Rachel R. Caspi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rachel R. Caspi has a total of 706 co-authors. Here are the top co-authors by number of shared publications:
Chi-Chao Chan
Laboratory of Immunology
63 shared publicationsPhyllis B. Silver
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892-1857, USA
46 shared publicationsReiko Horai
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA
35 shared publicationsMary J. Mattapallil
Immunoregulation Section, Laboratory of Immunology, NEI, NIH, Bethesda, MD 20892, USA
24 shared publicationsBarbara Wiggert
Laboratory of Cell and Molecular Biology, National Eye Institute, National Institutes of Health (NIH), Bethesda, MD 20892
21 shared publicationsC C Chan
Laboratory of Immunology, National Eye Institute, NIH, Bethesda, MD, 20892, U.S.A.
20 shared publications
Latest Publications
- Open Access
- 4 May 2026
- Published by Springer Nature in Research Square
Gut microbial interaction networks control autoimmunity to neuroretina
The gut microbiome influences the development of immune-mediated inflammatory diseases, including autoimmune uveitis, a sight-threatening ocular inflammation driven by retina-specific T cells1. Using a model of spontaneous autoimmune uveitis (sEAU) we showed that gut commensals provide immune stimuli that trigger disease2. Here we report that uveitis-promoting microbes are present in human gut flora and that colonization of germ-free (GF) mice with commensals from healthy human donors was sufficient to provoke disease. Severity of sEAU correlated with expansion of Akkermansia and contraction of short-chain fatty acid (SCFA)–producing Firmicutes, followed by decreased SCFA levels and a dominant gut Th1 effector response. Mechanistic gain-of-function experiments, enriching GF sEAU mice with Akkermansia, reproduced these microbiome, metabolite and immune phenotype shifts, and exacerbated disease, suggesting that Akkermansia promotes autoimmunity by outcompeting SCFA-producers and enhancing Th1-type responses. An inverse correlation between Akkermansia (Verrucomicrobia) and Firmicutes was also present in patients with uveitis, multiple sclerosis and Crohn’s disease. These findings reveal a stereotypic gut microbial interaction network that regulates systemic immune balance, and may represent an ecologically conserved mechanism through which the gut microbiome modulates autoimmune and inflammatory diseases. *Amy Zhang & Reiko Horai share equal contribution.
- 4 May 2026
- Published by Springer Nature in Research Square
Open AccessGut microbial interaction networks control autoimmunity to neuroretina
The gut microbiome influences the development of immune-mediated inflammatory diseases, including autoimmune uveitis, a sight-threatening ocular inflammation driven by retina-specific T cells1. Using a model of spontaneous autoimmune uveitis (sEAU) we showed that gut commensals provide immune stimuli that trigger disease2. Here we report that uveitis-promoting microbes are present in human gut flora and that colonization of germ-free (GF) mice with commensals from healthy human donors was sufficient to provoke disease. Severity of sEAU correlated with expansion of Akkermansia and contraction of short-chain fatty acid (SCFA)–producing Firmicutes, followed by decreased SCFA levels and a dominant gut Th1 effector response. Mechanistic gain-of-function experiments, enriching GF sEAU mice with Akkermansia, reproduced these microbiome, metabolite and immune phenotype shifts, and exacerbated disease, suggesting that Akkermansia promotes autoimmunity by outcompeting SCFA-producers and enhancing Th1-type responses. An inverse correlation between Akkermansia (Verrucomicrobia) and Firmicutes was also present in patients with uveitis, multiple sclerosis and Crohn’s disease. These findings reveal a stereotypic gut microbial interaction network that regulates systemic immune balance, and may represent an ecologically conserved mechanism through which the gut microbiome modulates autoimmune and inflammatory diseases. *Amy Zhang & Reiko Horai share equal contribution.
- Open Access
- 17 March 2026
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 215 (3)
Immune checkpoints in a genetically engineered mouse model of spontaneous autoimmune uveitis
Engineered mutant AireGW/+Lyn−/− C57BL/6 mice are a model of spontaneous autoimmunity in which 50% of mice develop highly destructive uveitis due to compromised central and peripheral T cell tolerance. The key retinal autoantigen in these mice is interphotoreceptor retinoid-binding protein (IRBP). The CD4+ T cells recognizing the dominant epitope of IRBP, called P2, from eye-draining lymph nodes of mice with or without uveitis and from the retinas of mice with uveitis, were characterized by single-cell RNA sequencing (scRNA-seq) and flow cytometry. Mice with uveitis had autoantigen-specific T cells in the eye-draining lymph node and in the retinas, exhibiting a range of activation states and a Th1 polarization, along with a small fraction of Tregs. Mice without uveitis had low numbers of P2-specific T cells in the eye-draining lymph nodes, and in most mice a substantial proportion of them were FoxP3+ Tregs. Transient depletion of Tregs by treatment of heathy AireGW/+Lyn−/− Foxp3DTR+/Y mice with diphtheria toxin resulted in rapid expansion of P2-specific CD4+ T cells in the eye-draining LN, and some of the Treg depleted mice went on to develop uveitis. Thus, development of inflammation in the retina was limited by a checkpoint in the eye-draining lymph nodes involving Tregs, and also apparently by an additional peripheral tolerogenic mechanism.
- 17 March 2026
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 215 (3)
Open AccessImmune checkpoints in a genetically engineered mouse model of spontaneous autoimmune uveitis
Engineered mutant AireGW/+Lyn−/− C57BL/6 mice are a model of spontaneous autoimmunity in which 50% of mice develop highly destructive uveitis due to compromised central and peripheral T cell tolerance. The key retinal autoantigen in these mice is interphotoreceptor retinoid-binding protein (IRBP). The CD4+ T cells recognizing the dominant epitope of IRBP, called P2, from eye-draining lymph nodes of mice with or without uveitis and from the retinas of mice with uveitis, were characterized by single-cell RNA sequencing (scRNA-seq) and flow cytometry. Mice with uveitis had autoantigen-specific T cells in the eye-draining lymph node and in the retinas, exhibiting a range of activation states and a Th1 polarization, along with a small fraction of Tregs. Mice without uveitis had low numbers of P2-specific T cells in the eye-draining lymph nodes, and in most mice a substantial proportion of them were FoxP3+ Tregs. Transient depletion of Tregs by treatment of heathy AireGW/+Lyn−/− Foxp3DTR+/Y mice with diphtheria toxin resulted in rapid expansion of P2-specific CD4+ T cells in the eye-draining LN, and some of the Treg depleted mice went on to develop uveitis. Thus, development of inflammation in the retina was limited by a checkpoint in the eye-draining lymph nodes involving Tregs, and also apparently by an additional peripheral tolerogenic mechanism.
- Open Access
Gut microbial interaction networks control autoimmunity to neuroretina
The gut microbiome influences the development of immune-mediated inflammatory diseases, including autoimmune uveitis, a sight-threatening ocular inflammation driven by retina-specific T cells 1 . Using a model of spontaneous autoimmune uveitis (sEAU) we showed that gut commensals provide immune stimuli that trigger disease 2 . Here we report that uveitis-promoting microbes are present in human gut flora and that colonization of germ-free (GF) mice with commensals from healthy human donors was sufficient to provoke disease. Severity of sEAU correlated with expansion of Akkermansia and contraction of short-chain fatty acid (SCFA)-producing Firmicutes, accompanied by decreased SCFA levels and a dominant gut Th1 effector response. Mechanistic gain-of-function experiments, enriching GF sEAU mice with A. muciniphila , reproduced these microbiome, metabolite and immune phenotype shifts, and exacerbated disease. We propose that Akkermansia promotes autoimmunity by outcompeting SCFA producers and enhancing Th1-type responses. An inverse correlation between Akkermansia (Verrucomicrobia) and Firmicutes was also present in fecal microbiota from patients with uveitis; related Verrucomicrobia/Firmicutes shifts were observed in multiple sclerosis and Crohn’s disease datasets. These findings reveal a stereotypic gut microbial interaction network that regulates systemic immune balance, and may represent an ecologically conserved mechanism through which the gut microbiome modulates autoimmune and inflammatory diseases.
Open AccessGut microbial interaction networks control autoimmunity to neuroretina
The gut microbiome influences the development of immune-mediated inflammatory diseases, including autoimmune uveitis, a sight-threatening ocular inflammation driven by retina-specific T cells 1 . Using a model of spontaneous autoimmune uveitis (sEAU) we showed that gut commensals provide immune stimuli that trigger disease 2 . Here we report that uveitis-promoting microbes are present in human gut flora and that colonization of germ-free (GF) mice with commensals from healthy human donors was sufficient to provoke disease. Severity of sEAU correlated with expansion of Akkermansia and contraction of short-chain fatty acid (SCFA)-producing Firmicutes, accompanied by decreased SCFA levels and a dominant gut Th1 effector response. Mechanistic gain-of-function experiments, enriching GF sEAU mice with A. muciniphila , reproduced these microbiome, metabolite and immune phenotype shifts, and exacerbated disease. We propose that Akkermansia promotes autoimmunity by outcompeting SCFA producers and enhancing Th1-type responses. An inverse correlation between Akkermansia (Verrucomicrobia) and Firmicutes was also present in fecal microbiota from patients with uveitis; related Verrucomicrobia/Firmicutes shifts were observed in multiple sclerosis and Crohn’s disease datasets. These findings reveal a stereotypic gut microbial interaction network that regulates systemic immune balance, and may represent an ecologically conserved mechanism through which the gut microbiome modulates autoimmune and inflammatory diseases.
- 11 September 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (11)
TLR2 supports γδ T cell IL-17A response to ocular surface commensals by metabolic reprogramming
The ocular surface is a mucosal barrier tissue colonized by commensal microbes, which tune local immunity by eliciting IL-17 from conjunctival γδ T cells to prevent pathogenic infection. The commensal Corynebacterium mastitidis (C. mast) elicits protective IL-17 responses from conjunctival Vγ4 T cells through a combination of γδ TCR ligation and IL-1 signaling. Here, we identify Vγ6 T cells as a major C. mast–responsive subset in the conjunctiva and uncover its unique activation requirements. We demonstrate that Vγ6 cells require both extrinsic (via dendritic cells) and intrinsic TLR2 stimulation for optimal IL-17A response. Mechanistically, intrinsic TLR2 signaling was associated with epigenetic changes and enhanced expression of genes involved in fatty acid oxidation to support Il17a transcription. We identify a key transcription factor, IκBζ, which is upregulated by TLR2 stimulation and is essential for this program. Our study highlights the importance of intrinsic TLR2 signaling in driving metabolic reprogramming and production of IL-17A in microbiome-specific mucosal γδ T cells.
- 11 September 2025
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 222 (11)
TLR2 supports γδ T cell IL-17A response to ocular surface commensals by metabolic reprogramming
The ocular surface is a mucosal barrier tissue colonized by commensal microbes, which tune local immunity by eliciting IL-17 from conjunctival γδ T cells to prevent pathogenic infection. The commensal Corynebacterium mastitidis (C. mast) elicits protective IL-17 responses from conjunctival Vγ4 T cells through a combination of γδ TCR ligation and IL-1 signaling. Here, we identify Vγ6 T cells as a major C. mast–responsive subset in the conjunctiva and uncover its unique activation requirements. We demonstrate that Vγ6 cells require both extrinsic (via dendritic cells) and intrinsic TLR2 stimulation for optimal IL-17A response. Mechanistically, intrinsic TLR2 signaling was associated with epigenetic changes and enhanced expression of genes involved in fatty acid oxidation to support Il17a transcription. We identify a key transcription factor, IκBζ, which is upregulated by TLR2 stimulation and is essential for this program. Our study highlights the importance of intrinsic TLR2 signaling in driving metabolic reprogramming and production of IL-17A in microbiome-specific mucosal γδ T cells.
- Open Access
- 30 May 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (6) , 115780
Ocular immune privilege in action: The living eye imposes unique regulatory and anergic gene signatures on uveitogenic T cells
- 30 May 2025
- Published by Elsevier in Cell Reports
- Vol. 44 (6) , 115780
Open AccessOcular immune privilege in action: The living eye imposes unique regulatory and anergic gene signatures on uveitogenic T cells
- Open Access
Laquinimod treatment attenuates EAU by inhibiting both the inductive and effector phases in an APC-dependent manner
Purpose: To evaluate the immunomodulatory effects on experimental autoimmune uveitis (EAU) of the aryl hydrocarbon receptor (AhR) agonist Laquinimod (LAQ), and its active metabolite DELAQ, with a focus on dendritic cell– and T cell–mediated mechanisms. Methods: EAU was induced in mice by active immunization or by adoptive transfer of activated T cells. Mice were treated with LAQ either from the time of immunization or from 7 days after. Effects of LAQ were examined in wild-type, global AhR-knockout, or dendritic cell–conditional AhR knockout mice. Direct vs. indirect effects of AhR agonism on dendritic cells and T cells were studied in vitro using DELAQ, a major active metabolite of LAQ. Results: LAQ treatment from Day 0 fully suppressed EAU, while delayed treatment (Day 7) provided only partial protection. In the adoptive transfer model, LAQ-treated recipients showed reduced pathology. Global AhR-deficient mice developed severe EAU comparable to that of wild-type mice, with an elevated Th17 response. LAQ-treated mice displayed increased frequencies of cDC1 and FoxP3⁺ regulatory T cells. In vitro, DELAQ activated AhR signaling and induced Ido1 and Ido2 expression in dendritic cells. DELAQ inhibited the activation of naïve and memory mouse T cells in an APC-dependent manner, as the response to anti-CD3/CD28 stimulation was unaffected. Importantly, DELAQ suppressed recall responses of human PBMC to tetanus toxoid. Conclusions: LAQ protects against EAU by acting on AhR-expressing antigen-presenting cells to impair both priming and reactivation of pathogenic T cells. Its active metabolite DELAQ does not suppress T cells directly, but re-programs dendritic cells toward a tolerogenic, IDO-expressing phenotype that promotes immune regulation.
Open AccessLaquinimod treatment attenuates EAU by inhibiting both the inductive and effector phases in an APC-dependent manner
Purpose: To evaluate the immunomodulatory effects on experimental autoimmune uveitis (EAU) of the aryl hydrocarbon receptor (AhR) agonist Laquinimod (LAQ), and its active metabolite DELAQ, with a focus on dendritic cell– and T cell–mediated mechanisms. Methods: EAU was induced in mice by active immunization or by adoptive transfer of activated T cells. Mice were treated with LAQ either from the time of immunization or from 7 days after. Effects of LAQ were examined in wild-type, global AhR-knockout, or dendritic cell–conditional AhR knockout mice. Direct vs. indirect effects of AhR agonism on dendritic cells and T cells were studied in vitro using DELAQ, a major active metabolite of LAQ. Results: LAQ treatment from Day 0 fully suppressed EAU, while delayed treatment (Day 7) provided only partial protection. In the adoptive transfer model, LAQ-treated recipients showed reduced pathology. Global AhR-deficient mice developed severe EAU comparable to that of wild-type mice, with an elevated Th17 response. LAQ-treated mice displayed increased frequencies of cDC1 and FoxP3⁺ regulatory T cells. In vitro, DELAQ activated AhR signaling and induced Ido1 and Ido2 expression in dendritic cells. DELAQ inhibited the activation of naïve and memory mouse T cells in an APC-dependent manner, as the response to anti-CD3/CD28 stimulation was unaffected. Importantly, DELAQ suppressed recall responses of human PBMC to tetanus toxoid. Conclusions: LAQ protects against EAU by acting on AhR-expressing antigen-presenting cells to impair both priming and reactivation of pathogenic T cells. Its active metabolite DELAQ does not suppress T cells directly, but re-programs dendritic cells toward a tolerogenic, IDO-expressing phenotype that promotes immune regulation.
- Open Access
Vitamin A is necessary for acquisition, but not for expression or progression, of CNS autoimmunity
Vitamin A (VitA) and its derivative retinoic acid (RA) are essential for immunological responses. In VitA deficient (VAD) mice, acquisition of effector responses is impeded, but little is known about maintenance and expression of previously acquired effector function under the VAD conditions. We examined the impact of VAD on progression of autoimmune diseases using two models of uveitis, experimental autoimmune uveitis (EAU) induced by active immunization and spontaneous uveitis in retina-specific T cell receptor transgenic (R161H) mice, and in the model of experimental autoimmune encephalomyelitis (EAE). VAD was induced by dietary lack of VitA from before birth, or by daily injections of a pan-RA receptor inhibitor BMS493 in adult mice fed with the standard diet. VAD mice were essentially resistant to induction of EAU or EAE and displayed impaired effector T cell responses. Defective priming/acquisition of effector function by VAD T cells was also evident. By contrast, spontaneously uveitic R161H mice fed with VAD diet, in which priming of pathogenic T cells occurs before onset of full VAD, only moderately attenuated uveitis compared to VitA sufficient R161H mice. To reconcile somewhat different results between induced model and spontaneous model of uveitis, we examined EAU in partial VAD mice or adoptive transfer into VAD hosts. The results supported that effector T cells primed in VitA-sufficient environment were able to function in VAD environment and induced EAU. We conclude that although priming of naïve T cells in the VAD environment is defective, effector function acquired under VitA sufficient conditions is maintained and can be expressed under VAD conditions. Because dietary lack of VitA is rarely profound and may be seasonal, our findings may shed light on immunity and autoimmunity in geographical regions where dietary VitA is limiting.
Open AccessVitamin A is necessary for acquisition, but not for expression or progression, of CNS autoimmunity
Vitamin A (VitA) and its derivative retinoic acid (RA) are essential for immunological responses. In VitA deficient (VAD) mice, acquisition of effector responses is impeded, but little is known about maintenance and expression of previously acquired effector function under the VAD conditions. We examined the impact of VAD on progression of autoimmune diseases using two models of uveitis, experimental autoimmune uveitis (EAU) induced by active immunization and spontaneous uveitis in retina-specific T cell receptor transgenic (R161H) mice, and in the model of experimental autoimmune encephalomyelitis (EAE). VAD was induced by dietary lack of VitA from before birth, or by daily injections of a pan-RA receptor inhibitor BMS493 in adult mice fed with the standard diet. VAD mice were essentially resistant to induction of EAU or EAE and displayed impaired effector T cell responses. Defective priming/acquisition of effector function by VAD T cells was also evident. By contrast, spontaneously uveitic R161H mice fed with VAD diet, in which priming of pathogenic T cells occurs before onset of full VAD, only moderately attenuated uveitis compared to VitA sufficient R161H mice. To reconcile somewhat different results between induced model and spontaneous model of uveitis, we examined EAU in partial VAD mice or adoptive transfer into VAD hosts. The results supported that effector T cells primed in VitA-sufficient environment were able to function in VAD environment and induced EAU. We conclude that although priming of naïve T cells in the VAD environment is defective, effector function acquired under VitA sufficient conditions is maintained and can be expressed under VAD conditions. Because dietary lack of VitA is rarely profound and may be seasonal, our findings may shed light on immunity and autoimmunity in geographical regions where dietary VitA is limiting.
- Open Access
Chromosome-scale genome assembly of B10.RIII, an autoimmune susceptible mouse strain
Background A vast majority of potential drug candidates are initially tested in mice before human trials, resulting in life-saving treatments and preventive measures. Hundreds of autoimmune disorders, including arthritis, lupus etc., affect millions of people all over the world. Studying those disorders using mouse models is crucial for understanding the disease mechanisms. Knowing the genome sequence of these mouse models would help with those vital studies. B10.RIII is one of the most susceptible mouse strains used as a model to understand autoimmune diseases but did not have its genome sequenced until now. Findings In this study, we generated the first, high-quality chromosome level genome sequence of B10.RIII, using a combination of long read, short read and optical mapping techniques. The B10.RIII genome sequence scored higher than the reference mouse genome both in assembly completeness and assembly quality. The B10.RIII genome annotation based on the reference genome identified about 98% of the known reference genes. Conclusions We believe the availability of B10.RIII genome sequence will help advance the understanding of autoimmune diseases, giving the researchers a better idea on its unique genetic makeup. Comparative studies of B10.RIII with other mouse models could also significantly enhance the power of these models towards their clinical applications.
Open AccessChromosome-scale genome assembly of B10.RIII, an autoimmune susceptible mouse strain
Background A vast majority of potential drug candidates are initially tested in mice before human trials, resulting in life-saving treatments and preventive measures. Hundreds of autoimmune disorders, including arthritis, lupus etc., affect millions of people all over the world. Studying those disorders using mouse models is crucial for understanding the disease mechanisms. Knowing the genome sequence of these mouse models would help with those vital studies. B10.RIII is one of the most susceptible mouse strains used as a model to understand autoimmune diseases but did not have its genome sequenced until now. Findings In this study, we generated the first, high-quality chromosome level genome sequence of B10.RIII, using a combination of long read, short read and optical mapping techniques. The B10.RIII genome sequence scored higher than the reference mouse genome both in assembly completeness and assembly quality. The B10.RIII genome annotation based on the reference genome identified about 98% of the known reference genes. Conclusions We believe the availability of B10.RIII genome sequence will help advance the understanding of autoimmune diseases, giving the researchers a better idea on its unique genetic makeup. Comparative studies of B10.RIII with other mouse models could also significantly enhance the power of these models towards their clinical applications.
- Open Access
Commensal-derived Trehalose Monocorynomycolate Triggers γδ T Cell-driven Protective Ocular Barrier Immunity
SUMMARY: Commensals shape host physiology through molecular crosstalk with host receptors. Identifying specific microbial factors that causally influence host immunity is key to understanding homeostasis at the host-microbe interface and advancing microbial-based therapeutics. Here, we identify trehalose monocorynomycolate (TMCM) from Corynebacterium mastitidis ( C. mast ) as a potent stimulator of IL-17 production by γδ T cells at the ocular surface. Mechanistically, TMCM-driven IL-17 responses require both IL-1 signals and γδ TCR signaling, which also supports endogenous γδ T cell IL-1R1 expression. Notably, synthetic TMCM alone is sufficient to mimic the effect of C. mast in inducing γδ T cell immunity and protect against pathogenic corneal infection. Our findings establish TMCM as a key mediator of commensal-driven immune defense, highlighting its potential as a γδ T cell adjuvant and a microbiome-informed therapeutic to enhance IL-17-driven protection at barrier sites such as the ocular surface. Graphical HIGHLIGHTS: Corynomycolates enable ocular C. mast colonization and protective IL-17 immunity TMCM drives IL-17 from γδ T cells through TCR and IL-1R signaling γδ TCR signaling maintains the expression of endogenous IL-1R1 Synthetic TMCM mimics the ability of C. mast to induce γδ T cell immunity in the eye TMCM protects against P. aeruginosa keratitis, highlighting its therapeutic potential
Open AccessCommensal-derived Trehalose Monocorynomycolate Triggers γδ T Cell-driven Protective Ocular Barrier Immunity
SUMMARY: Commensals shape host physiology through molecular crosstalk with host receptors. Identifying specific microbial factors that causally influence host immunity is key to understanding homeostasis at the host-microbe interface and advancing microbial-based therapeutics. Here, we identify trehalose monocorynomycolate (TMCM) from Corynebacterium mastitidis ( C. mast ) as a potent stimulator of IL-17 production by γδ T cells at the ocular surface. Mechanistically, TMCM-driven IL-17 responses require both IL-1 signals and γδ TCR signaling, which also supports endogenous γδ T cell IL-1R1 expression. Notably, synthetic TMCM alone is sufficient to mimic the effect of C. mast in inducing γδ T cell immunity and protect against pathogenic corneal infection. Our findings establish TMCM as a key mediator of commensal-driven immune defense, highlighting its potential as a γδ T cell adjuvant and a microbiome-informed therapeutic to enhance IL-17-driven protection at barrier sites such as the ocular surface. Graphical HIGHLIGHTS: Corynomycolates enable ocular C. mast colonization and protective IL-17 immunity TMCM drives IL-17 from γδ T cells through TCR and IL-1R signaling γδ TCR signaling maintains the expression of endogenous IL-1R1 Synthetic TMCM mimics the ability of C. mast to induce γδ T cell immunity in the eye TMCM protects against P. aeruginosa keratitis, highlighting its therapeutic potential